Guwahati, March 26, 2024: Drug maker Cipla Limited has forged an exclusive partnership with Sanofi India Limited to expand the reach of the country’s Central Nervous System (CNS) product range in India. The partnership will result in enhanced access to six CNS brands including Frisium, from Sanofi’s portfolio to patients and healthcare professionals across the country.
The strategic alliance will leverage Cipla’s strong marketing and sales personnel, distributors, institutions, and market outreach programs to drive growth for the CNS product range. It will also support Sanofi India’s efforts to continue bringing innovative therapies to patients with diverse needs.
“Enhancing access to highly efficacious and quality therapeutic solutions in CNS and bring value to patients across the country. Central Nervous System is one of the most challenging areas in medicine, and we believe this partnership is a significant step forward to address unmet needs of patients,” said Mr. Achin Gupta, Chief Executive Officer – One India Business, Cipla Limited.
<p>”Sanofi India’s CNS products are leaders in their respective categories. These well-established brands already improve lives of many patients across urban centres in the country. Cipla’s wide presence will enable us to expand the reach of this portfolio to healthcare professionals and patients across all India,” said Mr. Rodolfo Hrosz, Managing Director, Sanofi India Limited.
<p>The partnership is part of Cipla’s commitment to providing innovative and accessible healthcare solutions to patients across India. It also reflects the company’s commitment to promoting sustainable growth and development through its pharmaceutical industry operations.